Cereno Scientific receives patent approval in US for use of drug candidate CS1
Cereno Scientific has received a Notice of Allowance for the company’s patent application titled “Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation” from the US Patent Office, which means that the Patent Office intends to grant the company’s patent application. The pending patent approval provides Cereno Scientific with intellectual property rights for the company’s treatment concept and use of its drug candidate, CS1, in the US.
“It’s very gratifying to receive this information, which gives CS1 intellectual property rights and means that we now have approved patents in both our first and second patent families. This autumn we will also enter a national phase in a number of countries for our third patent family, which will further strengthen the protection for our treatment concept. The approved patent provides us with a platform for a significant market potential in the US, the world’s largest drug market — a market that, for drug-related treatment of thrombosis alone, has estimated sales of approximately USD 10 billion annually and continues to grow,” says Cereno Scientific CEO Sten R. Sörensen.
After formal approval, the US patent will be valid through 2035, with the possibility of a patent extension of an additional five years maximum.
For more information, please contact:
Sten R. Sörensen – CEO
Tel: +46 733 74 03 74
E-mail sten.sorensen@cerenoscientific.com
www.cerenoscientific.com
About Cereno Scientific AB
Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound and, as such, is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca’s BioVentureHub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock Market since June 2016 with the ticker CRNO B, ISIN SE0008241558.
This information is such that Cereno Scientific AB is required to make public in accordance with the EU’s market abuse regulation (MAR). The information was made available publically by the Company’s contact person on September 13th 2018.